tradingkey.logo

Coeptis Therapeutics Holdings Inc

COEPW
0.013USD
+0.000+3.10%
Close 01/09, 16:00ETQuotes delayed by 15 min
0.00Market Cap
--P/E TTM

Coeptis Therapeutics Holdings Inc

0.013
+0.000+3.10%

More Details of Coeptis Therapeutics Holdings Inc Company

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and advanced robotic process automation capabilities. Its Coeptis Technologies division is focused on diversifying and enhancing its growth potential. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Coeptis Therapeutics Holdings Inc Info

Ticker SymbolCOEPW
Company nameCoeptis Therapeutics Holdings Inc
IPO dateDec 17, 2020
CEO- -
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address105 Bradford Road, Suite 420
CityWEXFORD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code15090
Phone17249346467
Websitehttps://coeptistx.com/
Ticker SymbolCOEPW
IPO dateDec 17, 2020
CEO- -

Company Executives of Coeptis Therapeutics Holdings Inc

Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
--
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
--
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
25
552.87K
0.00%
-791.35K
2025Q3
26
552.87K
0.00%
-365.33K
2025Q2
27
918.20K
0.00%
+87.22K
2025Q1
26
830.98K
0.00%
-1.05M
2024Q4
29
1.01M
0.00%
-777.05K
2024Q3
33
1.78M
0.00%
-287.47K
2024Q2
34
2.07M
0.00%
-43.79K
2024Q1
34
2.12M
0.00%
-666.88K
2023Q4
33
1.49M
0.00%
-10.15K
2023Q3
31
1.50M
0.00%
-491.82K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Clear Street LLC
200.00
0%
+200.00
--
Jun 30, 2025
Clear Street Group Inc
4.99K
0%
+4.99K
--
Sep 30, 2025
IONIC Capital Management, L.L.C.
--
0%
-93.56K
-100.00%
Dec 31, 2024
TD Securities, Inc.
44.84K
0%
-118.00
-0.26%
Sep 30, 2025
HRT Financial LP
--
0%
-100.11K
-100.00%
Sep 30, 2024
Susquehanna International Group, LLP
--
0%
-54.68K
-100.00%
Sep 30, 2025
Meteora Capital LLC
114.87K
0%
-135.13K
-54.05%
Sep 30, 2025
RiverNorth Capital Management LLC
147.97K
0%
-1.93K
-1.29%
Sep 30, 2025
Walleye Trading, LLC
79.94K
0%
-50.23K
-38.59%
Sep 30, 2025
Skyview Investment Advisors, LLC
55.12K
0%
--
--
Jun 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data

FAQs

Who are the top five shareholders of Coeptis Therapeutics Holdings Inc?

The top five shareholders of Coeptis Therapeutics Holdings Inc are:
Clear Street LLC holds 200.00 shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 4.99K shares, accounting for 0.00% of the total shares.
IONIC Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
TD Securities, Inc. holds 44.84K shares, accounting for 0.00% of the total shares.
HRT Financial LP holds 0.00 shares, accounting for 0.00% of the total shares.

What are the top three shareholder types of Coeptis Therapeutics Holdings Inc?

The top three shareholder types of Coeptis Therapeutics Holdings Inc are:
Other

How many institutions hold shares of Coeptis Therapeutics Holdings Inc (COEPW)?

As of 2025Q4, 25 institutions hold shares of Coeptis Therapeutics Holdings Inc, with a combined market value of approximately 552.87K, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.

What is the biggest source of revenue for Coeptis Therapeutics Holdings Inc?

In --, the -- business generated the highest revenue for Coeptis Therapeutics Holdings Inc, amounting to -- and accounting for --% of total revenue.
KeyAI